John Hohneker, M.D., has served a member of the Board of Directors since January 2021. Dr. Hohneker served as Chief Executive Officer of Anokion, a privately held biotechnology company, from January 2018 to January 2021. Prior to joining Anokion, Dr. Hohneker was the President of Research and Development at FORMA Therapeutics Inc., a biotechnology company. Prior to FORMA, he held roles of increasing responsibility at Novartis AG, a pharmaceutical company, most recently as Senior Vice President and Global Head of Development for Immunology and Dermatology. Prior to joining Novartis, he held positions of increasing responsibility at Glaxo Wellcome and its legacy company, Burroughs Wellcome, both pharmaceutical companies. Dr. Hohneker received his B.A. from Gettysburg College and his M.D. from the University of Medicine and Dentistry of New Jersey at Rutgers Robert Wood Johnson Medical School.
John Hohneker, MD